Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

22.09 +0.11 (+0.50%)
Streaming Delayed Price Updated: 10:23 AM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,415
Open 21.81
Bid (Size) 21.93 (1)
Ask (Size) 22.09 (4)
Prev. Close 21.98
Today's Range 21.68 - 22.35
52wk Range 14.40 - 47.00
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded
Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks. 
Via Stocktwits
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-14.3%
-14.3%
1 Month
+4.1%
+4.1%
3 Month
+6.7%
+6.7%
6 Month
-12.5%
-12.5%
1 Year
-42.0%
-42.0%

More News

Read More
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
Via Benzinga
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
Via Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics
Via Benzinga
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
From Celldex Therapeutics, Inc.
Via GlobeNewswire
What Analysts Are Saying About Celldex Therapeutics Stock
Via Benzinga
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
Via Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
Via Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Via Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
What is the current price of Celldex Therapeutics, Inc. - Common Stock?
The current price of Celldex Therapeutics, Inc. - Common Stock is 22.09
When was Celldex Therapeutics, Inc. - Common Stock last traded?
The last trade of Celldex Therapeutics, Inc. - Common Stock was at 08/01/25 10:23 AM ET
What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.47B
How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
Celldex Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.